Brief: Gritstone Presents Positive Initial Phase 2 Data In Late-Line Solid Tumor Patients Treated With Kras-Directed Immunotherapy (Slate) At ESMO 2022

Gritstone bio

12/09/2022 12:10

Sept 12 (Reuters) - Gritstone bio Inc  GRTS.O :
    * GRITSTONE PRESENTS POSITIVE INITIAL PHASE 2 DATA IN
LATE-LINE
SOLID TUMOR PATIENTS TREATED WITH KRAS-DIRECTED IMMUNOTHERAPY
(SLATE) AT ESMO 2022
    * GRITSTONE BIO - SLATE VACCINES DEMONSTRATE EARLY EVIDENCE
OF
EFFICACY WITH 39% MOLECULAR RESPONSE RATE IN EVALUABLE PATIENTS
WITH LATE-LINE MSS-CRC, NSCLC

Source text for Eikon:  ID:nGNX6rtL2N 
Further company coverage:  GRTS.O 

 ((Reuters.Briefs@thomsonreuters.com;))